logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

< Back

Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

Drugs

Endocrine, Nutritional and Metabolic

September 2017


Sotagliflozin is a drug being developed to lower blood sugar levels in type 1 diabetes by increasing the amount of sugars excreted in the urine. It is taken once a day tablet in conjunction with insulin to prevent large rises and falls in blood sugar levels. This may be especially useful for people who cannot control their blood sugar levels with insulin alone. Sotagliflozin is currently in clinical trials which have shown that sotagliflozin has the potential to reduce and control blood sugar levels when taken with insulin.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts